Podcast CME Course Information

Exam: Exam 433: Current treatment practice of Guillain-Barré syndrome

Issue: July 02, 2019

Learning Objectives

Current treatment practice of Guillain-Barré syndrome

Upon completion, listeners will be aware of common treatment practices in Guillain-Barre syndrome and outcomes.

Recommended Audience

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

Core Competencies

  • Patient Care
  • Medical Knowledge

Disclosures

Program Accreditations Subcommittee (PAS) is responsible for reviewing and evaluating all CME programs. Joseph F. Kass, MD, JD, FAAN, has received personal compensation for activities as an expert witness in litigation and in an editorial capacity for the American Academy of Neurology. Barney J. Stern, MD, FAAN, has received personal compensation for book chapter contributions. The other members of the committee (Samir Belagaje, MD; J. Clay Goodman, MD, FAAN; Omotola A. Hope, MD; Shannon M. Kilgore, MD, FAAN) and AAN staff (Kristine Mitchell) report no disclosures. Robert A. Gross, MD, PhD, FAAN, has received funding for travel and/or speaker honoraria from the American Academy of Neurology; receives a stipend as Editor-in-Chief of Neurology; has received consultant fees from GlaxoSmithKline and Harris Interactive; has served on speakers' bureaus for Abbott, UCB, and GlaxoSmithKline; has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus, but has ceased participation in industry-sponsored clinical trials and speakers' bureaus since his appointment as Neurology EIC in 2010; and has received research support from the Department of the Army, UCBPharma, and University of Rochester Medical Center/NIH. Dr. Stacey Clardy serves as Podcast Editor for Neurology® and has received research support forWestern Institute for Biomedical Research (WIBR). Dr. Jeff Ratliff serves as Podcast Deputy Editor for Neurology andreceived a speaker honorarium from Haverford College. AAN staff members editing the test (P Baskin, L Kleffman, K Aman Ramm) have no disclosures. The CME Journal Editors who have reviewed the exam are James WM Owens Jr., MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology and Adam Kelly, MD, who has served as Guest Editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.

Dr. Michelle Mauermann has served on the IONIS Pharmaceuticals Scientific Advisory Board; has served as the Section Editor for Mayo Clinic Proceedings; has received publishing royalties from Oxford for Autonomic Neurology; and has received commercial research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals. Dr. Bart C. Jacobs has received travel funding from Baxter International Inc.; has served on the editorial board of Journal of the Peripheral Nervous System; has received commercial research funding from Grifols, CSL-Behring, Baxalta, Annexon, and Hansa Medical AB; has received governmental research support from Netherlands Organization for Health Research and Development; has received academic research support from Horizon 2020; has received foundation/society research support from Erasmus MC, Prinses Beatrix Spierfonds, and GBS-CIDP Foundation International; and serves on the Executive Board and Medical Advisory Board for the GBS-CIDP Foundation International, on the Executive Board of the Inflammatory Neuropathy Consortium, the Scientific Advisory Boards of the Dutch ALS Foundation, and the Dutch MS Foundation. Dr. Matthew Harms has served on the scientific advisory boards for Biogen, Maze Therapeutics, and Sanofi-Genzyme; has received funding for travel or speaking for Sanofi-Genzyme, AANEM, the AAN, and the MDA; has served on the editorial boards for Journal of Neuromuscular Diseases, Muscle & Nerve, and Neurohospitalist; has served as a consultant for Leerink Partners, Trinity Partners, and UPenn Rare Disease; has received commercial research support from Biogen; has received foundation/society research support from ALS Association, Project ALS, and Target ALS; and has participated in legal proceedings for Burke Wise Morrisey Kovey, Haar + Woods, the MTA of NYC, Silver Golub and Teitell, and American Family Mutual Insurance. Dr. Guy Rouleau has received governmental research support from the CIHR Foundation, the ALS Society of Canada, and the ALS Association; and has received foundation/society research support from the Canadian Institute of Health Research, Genome Quebec, ALS-Brain Canada, Brain Canada, and the Canadian Institute of Health Research.

CME Expiration

CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.

Accreditation

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit™

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Copyright

The American Academy of Neurology holds copyright for all materials in this exam.

Confidentiality

Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.

Hardware and Software Requirements

A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.

Start this exam

For More Information

Patty Baskin

Executive Editor, Neurology®
pbaskin@aan.com
(612) 928-6021